Dive into the cutting-edge realm of nephrology as we explore the transformative potential of extracorporeal photopheresis in solid organ transplantation, unveiling its current applications and visionary future directions.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
The use of extracorporeal photopheresis in solid organ transplantation – current status and future directions.
Barten et al., Am J Transplant 2024
<!– DOI: 10.1016/j.ajt.2024.03.012 //–>
https://doi.org/10.1016/j.ajt.2024.03.012
This review highlights the potential of Extracorporeal Photopheresis (ECP) as an innovative therapeutic option for the prevention and management of organ rejection in solid organ transplantation. ECP, recognized in international guidelines for heart (HTx) and lung (LTx) transplantation, is gaining attention for its immunomodulatory and immunosuppressive-sparing effects. This is particularly significant given the adverse effects associated with current immunosuppressive therapies. The review underscores the need for treatments that support graft tolerance while reducing reliance on immunosuppression. ECP’s role is also being explored in kidney and liver transplantation, indicating its broader applicability. The emphasis on ECP is due to its potential benefits in high-risk patients who have comorbidities, infectious complications, or malignancies, showcasing its importance in improving therapeutic strategies for allograft rejection. This information is crucial as it points towards a shift in managing organ rejection, focusing on minimizing adverse effects while ensuring effective immunomodulation.